SNDX241220C25000
- 0.15
- 0.000.00%
Syndax Pharmaceuticals Newsroom
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
Trending Stocks Today | Molecular Templates Surges 43.71% Post-Market
Analysts Supportive of Kura/Kirin Deal Despite Major Selloff in Shares
J.P. Morgan Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Announces Target Price $38
Syndax Pharmaceuticals Is Maintained at Buy by Citigroup
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
Scotiabank Maintains Syndax Pharmaceuticals(SNDX.US) With Hold Rating, Maintains Target Price $18
A Quick Look at Today's Ratings for Syndax Pharmaceuticals(SNDX.US), With a Forecast Between $33 to $51
Express News | Syndax Pharmaceuticals Inc : Citigroup Raises Target Price to $45 From $37
Syndax Pharmaceuticals (SNDX) Gets a Buy From Barclays
Syndax Pharmaceuticals' Promising Outlook: Revumenib Approval and Market Potential Justify Buy Rating
Express News | Syndax Pharmaceuticals Shares Rise 4.2% After FDA Approves Co's Blood Cancer Drug
Roku To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday
Syndax Pharmaceuticals (SNDX) Gets a Buy From TD Cowen
Express News | HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $51
Express News | Syndax Pharmaceuticals Inc : Jefferies Raises Target Price to $43 From $37
Early FDA Approval of Revuforj Boosts Syndax Pharmaceuticals' Prospects and Supports Overweight Rating
Trending Stocks Today | DDC Enterprise Surges 48.83% Post-Market
Express News | Syndax Pharmaceuticals: Before Commercial Availability of 25 Mg Tablets, Oral Solution of Revumenib to Be Available Through Expanded Access Program
Express News | Syndax Pharmaceuticals - 25 Mg Revuforj Tablets Expected to Be Commercially Available in Late Q1 or Early Q2 of 2025